Active Filter(s):
Details:
Fathom joining Consegna, will accelerate the clinical development of combined LAI (long-acting injectables) focused on several aspects of pain signaling pathways. Fathom Pharma develops new treatments for chronic pain that includes FP01, as a treatment paradigm.
Lead Product(s): FP01
Therapeutic Area: Neurology Product Name: FP01
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Consegna Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 19, 2022